Reversion analysis reveals the immunogenicity in vivo of a poorly MHC I-binding cancer neoepitope. Reversion analysis reveals the immunogenicity in vivo of a poorly MHC I-binding cancer neoepitope

A mutation that results in tumor rejection activity in a neoepitope (which is a poor binder of Kd) influences the immunogenicity of the tumor as a whole. Our results demonstrate the activity in vivo of a poorly-MHC I-binding cancer neoepitope. Overall design: Examination of tumor microenvironment (TME) of different CRISPR edited mouse Meth A fibrosarcoma (REV, MUT1 and MUT2) as well as TME of mice immunized with mutant Ccdc85c and Alms1.